University Hospital Vall d'Hebron
Barcelona, 08035, Spain
Location status: Recruiting
NCT Number: NCT07488806
The objective of this natural history study is to comprehensively characterize the disease progression and clinical features of nemaline myopathies. The study aims to establish a well-defined cohort of patients in Spain, enabling long-term follow-up and facilitating recruitment for future clinical trials.
Interested in participating?
Request InfoAll sexes
Observational
Barcelona, 08035, Spain
Location status: Recruiting
The aims of the study are:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Ultrasound guided evaluation of 28 muscles evaluated accross different body regions, assessed using the Heckmatt gradinf system (semiquantitative scale).
Evaluation of patients motor function using motor scales (CHOP-INTEND, MFM32, HINE-2, NSAA, PDSM-3, RFF, 10m walk, PUL)
Complete physical evaluations including muscle power and goniometry measurements
Assessment of ventilatory, cardiac, nutritional, and other support needs
Assessment of quality of life
Video/photos with the aim is to record actions such as lifting a glass, raising arms above the head, getting up from the floor or a chair, walking, or running, in order to later analyze in detail how these movements are performed.
Assessment of bulbar funcionality: feeding devices, nutritional status.
Motor milestones age of acquisition and loss (if applicable)
Time frame: Change from baseline through study completion, an average of 5 years
A standardized muscle ultrasound protocol of assessment is performed (whole body). Muscle images are scored using the Heckmatt scale (score 1-4):
Time frame: Change from baseline through study completion, an average of 5 years
The CHOP-INTEND assesses a child's ability to move their body in a lying down position, supported sitting, and assisted rolling through 16 items. Scores range from 0 to 64, with higher scores indicating better motor function.
Change in motor function assessed using age-appropriate validated motor scales and dependent on patient's ability.
Time frame: Change from baseline through study completion, an average of 5 years
This is a 37-item measure of infant developmental motor milestones that will be performed in participants aged 0-24months. Scores are interpreted in relation to optimality scores and cut-off scores for the participant's age. Higher scores represented higher function.
Time frame: Change from baseline through study completion, an average of 5 years
Change in motor function assessed using age-appropriate validated motor scales and dependent on patient's ability. PDMS-3 measures various motor abilities in young children. Four types of normative scores are yielded: age equivalents, percentile ranks, subtest scaled scores, and composite index scores. Higher scores indicate higher level of function.
Time frame: Change from baseline through study completion, an average of 5 years
Change in motor function assessed using age-appropriate validated motor scales and dependent on patient's ability. This motor function assessment consists of 32 items organized in three dimensions: standing position and transfers, axial and limb proximal motor function, and limb distal motor function. Total scores are given between 0-100, with 0 indicating severe functional impairment and 100 indicating no functional impairment.
Time frame: Change from baseline through study completion, an average of 5 years
Change in motor function assessed using age-appropriate validated motor scales and dependent on patient's ability. Scores in the NSAA scale range from 0 to 34, with higher scores indicating better motor function.
Time frame: Change from baseline through study completion, an average of 5 years
Change in upper limb function assessed using the Performance of Upper Limb (PUL) scale. Higher scores indicate better function.
Time frame: Change from baseline through study completion, an average of 5 years
Respiratory function will be assessed longitudinally using age-appropriate measures depending on patient ability. Respiratory status will include ventilatory support requirements (none, non-invasive ventilation, or invasive ventilation) and time on/off ventilator, when feasible. Forced vital capacity (FVC), expressed as percent predicted for age and sex, will be used when spirometry is possible.
Time frame: Change from baseline through study completion, an average of 5 years
Assessment of nutritional status over time through indicators such as feeding method (oral versus enteral feeding) and need for nutritional support. Swallowing status and dietary modifications will be recorded when applicable. Changes from baseline will be analyzed to evaluate nutritional progression and feeding outcomes.
Time frame: Change from baseline through study completion, an average of 5 years
Assessment of patient or caregiver-reported quality of life using validated questionnaires appropriate for age and functional status, including standardized health-related quality of life instruments (the Clinical Global Impression-Severity [CGI-S], the Clinical Global Impression-Change [CGI-C], Patient Global Impression of Change [PGI-C], and Patient Global Impression of Severity [PGI-S]). Total scores and domain-specific scores will be analyzed. Changes from baseline will be evaluated to assess perceived health status and daily functioning.
Contact information is provided by the study sponsor or research team.
Hospital Universitari Vall d'Hebron Research Institute
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06157268
Central Core Disease, Centronuclear Myopathy
Nijmegen, Gelderland, Netherlands
View Trial DetailsNCT00272883
Central Core Disease, Centronuclear Myopathy
Boston, Massachusetts, United States
View Trial DetailsNCT07478172
Amyotrophic Lateral Sclerosis, Autoimmune Diseases
Columbia, Missouri, United States
View Trial DetailsNCT06670378
Muscular Diseases, Musculoskeletal Diseases
London, United Kingdom
View Trial Details